Patented Co-crystals Oscity BioSciences holds two granted U.S. patents covering co-crystal solid forms of THC and related cannabinoids, offering a unique IP position and potential licensing opportunities for pharmaceutical partners seeking differentiated cannabinoid formulations.

cGMP Facility Operates from an FDA-certified cGMP facility in Foley, Alabama, signaling readiness for clinical-grade production and potential contract manufacturing services for partners pursuing regulatory-compliant cannabinoid drugs.

Full-spectrum IP Portfolio extends across cannabinoids such as CBN, CBG, CBDV, etc., enabling cross-cannabinoid licensing deals and collaboration opportunities for diverse therapeutic programs in pain, epilepsy, inflammation, and neuroprotection.

Small to Mid-market With 11-50 employees and revenue in the 1M–10M range, Oscity presents as a nimble partner for targeted collaborations, early-stage development programs, and exclusive licensing deals without large-scale enterprise overhead.

Tech-forward Emphasizes proprietary extraction for high-purity co-crystals and employs modern tech stack and analytics, presenting opportunities to integrate with CRO/CMO ecosystems, data-driven research partnerships, and digital marketing for scientific collaborations.